|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
2.
|
Choong N and Vokes E: Expanding role of
the medical oncologist in the management of head and neck cancer.
CA Cancer J Clin. 58:32–53. 2008.
|
|
3.
|
Karar J and Maity A: Modulating the tumor
microenvironment to increase radiation responsiveness. Cancer Biol
Ther. 8:1994–2001. 2009.
|
|
4.
|
Mottram JC: A factor of importance in the
radio sensitivity of tumours. Br J Radiol. 9:606–614. 1936.
|
|
5.
|
Thomlinson RH and Gray LH: The
histological structure of some human lung cancers and the possible
implications for radiotherapy. Br J Cancer. 9:539–549. 1955.
|
|
6.
|
Nordsmark M, Overgaard M and Overgaard J:
Pretreatment oxygenation predicts radiation response in advanced
squamous cell carcinoma of the head and neck. Radiother Oncol.
41:31–39. 1996.
|
|
7.
|
Rajendran JG, Mankoff DA, O’Sullivan F, et
al: Hypoxia and glucose metabolism in malignant tumors: evaluation
by [18F] fluoromisonidazole and [18F]fluorodeoxyglucose positron
emission tomography imaging. Clin Cancer Res. 10:2245–2252.
2004.
|
|
8.
|
Bentzen L, Keiding S, Horsman MR, Falborg
L, Hansen SB and Overgaard J: Feasibility of detecting hypoxia in
experimental mouse tumours with 18F-fluorinated tracers and
positron emission tomography - a study evaluating
[18F]fluoro-2-deoxy-D-glucose. Acta Oncol. 39:629–637. 2000.
|
|
9.
|
Cooper RA, Carrington BM, Loncaster JA, et
al: Tumour oxygenation levels correlate with dynamic
contrast-enhanced magnetic resonance imaging parameters in
carcinoma of the cervix. Radiother Oncol. 57:53–59. 2000.
|
|
10.
|
Hoskin PJ, Saunders MI, Goodchild K,
Powell ME, Taylor NJ and Baddeley H: Dynamic contrast enhanced
magnetic resonance scanning as a predictor of response to
accelerated radiotherapy for advanced head and neck cancer. Br J
Radiol. 72:1093–1098. 1999.
|
|
11.
|
Ferreira MB, De Souza JA and Cohen EE:
Role of molecular markers in the management of head and neck
cancers. Curr Opin Oncol. 23:259–264. 2011.
|
|
12.
|
Melillo G: Inhibiting hypoxia-inducible
factor 1 for cancer therapy. Mol Cancer Res. 4:601–605. 2006.
|
|
13.
|
Aebersold DM, Burri P, Beer KT, et al:
Expression of hypoxia-inducible factor-1alpha: a novel predictive
and prognostic parameter in the radiotherapy of oropharyngeal
cancer. Cancer Res. 61:2911–2916. 2001.
|
|
14.
|
Yeo EJ, Chun YS and Park JW: New
anticancer strategies targeting HIF-1. Biochem Pharmacol.
68:1061–1069. 2004.
|
|
15.
|
Semenza GL: Intratumoral hypoxia,
radiation resistance, and HIF-1. Cancer Cell. 5:405–406. 2004.
|
|
16.
|
Rohwer N, Lobitz S, Daskalow K, et al:
HIF-1alpha determines the metastatic potential of gastric cancer
cells. Br J Cancer. 100:772–781. 2009.
|
|
17.
|
Airley RE, Phillips RM, Evans AE, et al:
Hypoxia-regulated glucose transporter Glut-1 may influence
chemosensitivity to some alkylating agents: Results of EORTC (First
Translational Award) study of the relevance of tumour hypoxia to
the outcome of chemotherapy in human tumour-derived xenografts. Int
J Oncol. 26:1477–1484. 2005.
|
|
18.
|
Isa AY, Ward TH, West CM, Slevin NJ and
Homer JJ: Hypoxia in head and neck cancer. Br J Radiol. 79:791–798.
2006.
|
|
19.
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003.
|
|
20.
|
Welsh S, Williams R, Kirkpatrick L,
Paine-Murrieta G and Powis G: Antitumor activity and
pharmacodynamic properties of PX-478, an inhibitor of
hypoxia-inducible factor-1alpha. Mol Cancer Ther. 3:233–244.
2004.
|
|
21.
|
Xia Y, Choi HK and Lee K: Recent advances
in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem.
49:24–40. 2012.
|
|
22.
|
Adachi M, Cui C, Dodge CT, Bhayani MK and
Lai SY: Targeting STAT3 inhibits growth and enhances
radiosensitivity in head and neck squamous cell carcinoma. Oral
Oncol. Jul 6–2012, (E-pub ahead of print).
|
